Abstract
Background
Dihydropyrimidine dehydrogenase (DPD) is an enzyme that catabolizes 5-fluorouracil (5-FU). The effect of DPD inhibitory fluoropyrimidines (DIF) is presumably related to DPD activity. We studied the efficacy of DIF (tegafur + uracil [UFT], tegafur + gimeracil + osteracil [S-1 (TS-1®)]) relative to DPD activity, with other fluoropyrimidines as controls.
Methods
The efficacy of DIF relative to DPD activity was evaluated in 58 gastric cancer patients who received postoperative administration of fluoropyrimidines, consisting of DIF in 42 patients (UFT in 23; S-1 in 19) and non-DIF in 16 patients.
Results
In patients with low DPD activity (under 40 U/mg protein), curative potential tended to be lower for DIF than for non-DIF, but the survival rate was the same for both. In patients with high DPD activity (40 U/mg protein or more), such a tendency was not detected. In a comparison between those treated with UFT and those treated with S-1, prognosis was better in the latter group, in spite of their predominance of lower curative potentials of B or C. In 27 patients with measurable lesions, a partial response (PR) or higher response occurred in 33% (5/15) of those with low DPD activity, and in 17% (2/12) of those with high DPD activity. In the patients with low DPD activity, non-DIF induced no change (NC) in 17% (1/6), and progressive disease (PD) in the rest. UFT induced PD in all 5 patients, while S-1 induced a response rate of 44% (7/16), with NC in 25% (4/16). In the patients with high DPD activity, on the other hand, non-DIF (n = 3) and UFT (n = 3) induced PD in all the patients, while S-1 induced PR in 33% (2/6) and NC or a higher response in 67% (4/6).
Conclusion
It is recommended to use S-1 rather than UFT in patients with high DPD activity. Measurement of DPD was useful in drug selection.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
RB Diasio (1999) ArticleTitleClinical implications of dihydropyrimidine dehydrogenase inhibition Oncology (Huntingt) 13 17–21 Occurrence Handle1:STN:280:DyaK1MzntV2nsw%3D%3D
H Ishitsuka M Miwa K Takemoto K Fukuoka A Itoga HB Maruyama (1980) ArticleTitleRole of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine Gann 71 112–23 Occurrence Handle6445847 Occurrence Handle1:CAS:528:DyaL3cXktVSltrk%3D
S Ohwada T Ogawa M Izumi T Inoue O Teshigawara T Ikeya et al. (1997) ArticleTitleEffects of 5′-DFUR and OK-432 on cytokines and thymidine phosphorylase in tumor tissue of gastric cancer patients Anticancer Res 17 2313–8 Occurrence Handle9216708 Occurrence Handle1:CAS:528:DyaK2sXkvFyltrw%3D
JR Bertino WL Sawicki CA Lindquist VS Gupta (1977) ArticleTitleSchedule-dependent antitumor effects of methotrexate and 5-fluorouracil Cancer Res 37 327–8 Occurrence Handle830420 Occurrence Handle1:CAS:528:DyaE2sXotlKqsg%3D%3D
RM Evans JD Laskin MT Hakala (1981) ArticleTitleEffect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil Cancer Res 41 3288–95 Occurrence Handle6973389 Occurrence Handle1:CAS:528:DyaL3MXlvVSks74%3D
D Machover E Goldschmidt P Chollet G Metzger J Zittoun J Marquet et al. (1986) ArticleTitleTreatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid J Clin Oncol 4 685–96 Occurrence Handle3517242 Occurrence Handle1:STN:280:BimC1MfotlU%3D
H Majima (1980) ArticleTitlePhase I and preliminary phase II study of coadministration of uracil and FT-207 (UFT therapy) Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 7 1383–7
DP Baccanari ST Davis VC Knick T Spector (1993) ArticleTitle5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil Proc Natl Acad Sci U S A 90 11064–8 Occurrence Handle8248211 Occurrence Handle1:CAS:528:DyaK2cXmvV2qsg%3D%3D
T Shirasaka Y Shimamato H Ohshimo M Yamaguchi T Kato K Yonekura et al. (1996) ArticleTitleDevelopment of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548–57 Occurrence Handle8862723 Occurrence Handle1:CAS:528:DyaK28Xltleru78%3D
T Shirasaka F Fujita M Fujita M Fukushima T Taguchi S Fujii (1990) ArticleTitleAntitumor activity and metabolism of BOF-A2, a new 5-fluorouracil derivative, with human cancers xenografted in nude mice Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 17 1871–6 Occurrence Handle1:CAS:528:DyaK3MXhvF2it7c%3D
T Sasaki (1997) ArticleTitleNew anti-cancer drugs for gastrointestinal cancers Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 24 1925–31 Occurrence Handle1:CAS:528:DyaK2sXmvVGgsr4%3D
K Tatsumi M Fukushima T Shirasaka S Fujii (1987) ArticleTitleInhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts Jpn J Cancer Res 78 748–55 Occurrence Handle3114201 Occurrence Handle1:CAS:528:DyaL2sXlvFSntL8%3D
K Mori M Hasegawa M Nishida H Toma M Fukuda T Kubota et al. (2000) ArticleTitleExpression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues Int J Oncol 17 33–8 Occurrence Handle10853015 Occurrence Handle1:CAS:528:DC%2BD3cXksV2rurs%3D
K Maruyama M Sasako T Sano H Katai I Kino Y Kato et al. (1995) Operative procedures M Nishi Y Omori K Miwa (Eds) Japanese classification of gastric carcinoma EditionNumberFirst English Ed. Kanehara Tokyo 14–16
JR Bateman RP Pugh FR Cassidy GJ Marshall LE Irwin (1971) ArticleTitle5-Fluorouracil given once weekly: comparison of intravenous and oral administration Cancer 28 907–13 Occurrence Handle5111743 Occurrence Handle1:STN:280:CS2D383ktV0%3D
S Saji K Aiba H Araki K Sasaki T Shirasaka M Sowa et al. (1997) ArticleTitleCurrent status of low-dose CDDP. 5-FU therapy for solid malignant tumors — nationwide questionnaire survey Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 24 1892–900 Occurrence Handle1:STN:280:DyaK1c%2FhtFejug%3D%3D
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Usuki, H., Ishimura, K., Yachida, S. et al. Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines. Gastric Cancer 6 (Suppl 1), 66–70 (2003). https://doi.org/10.1007/s10120-003-0225-8
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10120-003-0225-8